|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-1-19
|
|
pubmed:abstractText |
This pediatric phase I trial of tipifarnib determined the maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of tipifarnib in children with refractory solid tumors and neurofibromatosis type 1 (NF1) -related plexiform neurofibromas.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:ArceciRobert JRJ,
pubmed-author:BalisFrank MFM,
pubmed-author:BlaneySusan MSM,
pubmed-author:EndDavidD,
pubmed-author:FoxElizabethE,
pubmed-author:GillespieAndreaA,
pubmed-author:JayaprakashNaliniN,
pubmed-author:PalumboJoseph SJS,
pubmed-author:PitneyAaronA,
pubmed-author:SalzerWanda LWL,
pubmed-author:WhitcombPatriciaP,
pubmed-author:WidemannBrigitte CBC,
pubmed-author:ZannikosPeterP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
507-16
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16421428-Adolescent,
pubmed-meshheading:16421428-Antineoplastic Agents,
pubmed-meshheading:16421428-Bone Marrow,
pubmed-meshheading:16421428-Child,
pubmed-meshheading:16421428-Child, Preschool,
pubmed-meshheading:16421428-Drug Administration Schedule,
pubmed-meshheading:16421428-Drug Eruptions,
pubmed-meshheading:16421428-Enzyme Inhibitors,
pubmed-meshheading:16421428-Farnesyltranstransferase,
pubmed-meshheading:16421428-Female,
pubmed-meshheading:16421428-Gastrointestinal Tract,
pubmed-meshheading:16421428-Humans,
pubmed-meshheading:16421428-Male,
pubmed-meshheading:16421428-Neurofibroma, Plexiform,
pubmed-meshheading:16421428-Neurofibromatosis 1,
pubmed-meshheading:16421428-Quinolones,
pubmed-meshheading:16421428-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
|
|
pubmed:affiliation |
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA. widemanb@mail.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I,
Research Support, N.I.H., Intramural
|
